RxDoctor Payments Data

Claude Innocent, MD

Internal Medicine · Miami, FLNPI 1639151368

Payments from drug & device makers

$930in general payments, 2019–2025

Across 42 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$635
  • Novo Nordisk$117
  • GSK$65
  • Gilead$43
  • Pfizer$22
  • Johnson & Johnson$18
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$930100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$930 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$7,501
Medicare patients
38
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$87,407
TriumeqAbacavir/Dolutegravir/Lamivudi19$69,853
Tresiba Flextouch U-100Insulin Degludec44$45,069
JardianceEmpagliflozin25$42,632
XareltoRivaroxaban20$22,337
FarxigaDapagliflozin Propanediol13$19,952
Tresiba Flextouch U-200Insulin Degludec21$18,316
MyrbetriqMirabegron16$9,320
LumiganBimatoprost15$6,873
Breo ElliptaFluticasone/Vilanterol11$5,939
Atorvastatin Calcium600$5,732
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$3,947
Amlodipine Besylate458$3,098
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid28$2,763
Varenicline Tartrate13$2,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$87,40789 claims
Viiv Healthcare CompanyTriumeq$635$69,85319 claims
Johnson & JohnsonXarelto$18$22,33720 claims
GSKBreo Ellipta$65$5,93911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →